STCube, Inc.
Financials
Valuation Metrics
STCube, Inc.'s Market Cap is ₩5119B. At end of 2025 it was ₩5575B. Ranked #473 of 2,419 in KR market (top 20%), #177 of 1,638 on KOSDAQ (top 11%), #40 of 246 in Technology Hardware & Equipment (top 16%) by Market Cap.
Investment Metrics(as of 2026-10-08)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 511.91B KRW | KR#473/2,419 Sec#40/246 |
| Revenue | 7.11B KRW | KR#2,315/2,419 Sec#242/246 |
| Net Income | -24.07B KRW | KR—/2,419 Sec—/246 |
| Total Assets | 90.23B KRW | KR#1,859/2,419 Sec#184/246 |
| Net Assets | 72.12B KRW | KR#1,662/2,419 Sec#159/246 |
| Employees | 16 | KR#2,268/2,419 Sec#237/246 |
| Value | ||
| P/B | 7.10x | KR#2,296/2,419 Sec#228/246 |
| P/S | 72.04x | KR#2,378/2,419 Sec#245/246 |
| FCF Yield | -4.04% | KR—/2,419 Sec—/246 |
| Profitability | ||
| ROE | -33.37% | KR#2,207/2,419 Sec#225/246 |
| ROA | -26.67% | KR#2,293/2,419 Sec#237/246 |
| Op. Margin | -368.31% | KR#2,352/2,419 Sec#245/246 |
| Revenue Growth | -16.53% | KR#2,075/2,419 Sec#207/246 |
| Financial Health | ||
| Debt Ratio | 25.11% | KR#487/2,419 Sec#52/246 |
| Total Debt | 0 KRW | KR—/2,419 Sec—/246 |
| FCF | -20.68B KRW | KR#1,899/2,419 Sec#192/246 |
| Cash | 16.93B KRW | KR#1,358/2,419 Sec#137/246 |
| Current Ratio | 15.21x | KR#45/2,419 Sec#6/246 |
| Performance | ||
| 1Y Return | 2.45% | KR#708/2,419 Sec#101/246 |
| 1M Return | -6.23% | KR#1,874/2,419 Sec#205/246 |
| From 52W High | -66.53% | KR#2,108/2,419 Sec#217/246 |
| 1Y MDD | -70.63% | KR#2,016/2,419 Sec#192/246 |
| Trading | ||
| Volume | 106,275 shares | KR#759/2,419 Sec#89/246 |
| Trading Value | 793.5M KRW | KR#820/2,419 Sec#88/246 |
| Foreign Own. | 5.66% | KR#772/2,419 Sec#90/246 |
| Per Share | ||
| EPS | -354 KRW | KR—/2,419 Sec—/246 |
| BPS | 1,061 KRW | KR#2,298/2,419 Sec#223/246 |
Company Info
STCube, established in 1989 and listed on KOSDAQ in 2001, is a diversified company engaged in bio, cosmetics, and IT distribution. In collaboration with STCube Pharmaceuticals, Inc., it develops anti-cancer immunotherapies and conducts cosmetics manufacturing, sales, and distribution under its brand, C-NALS. The company is actively conducting global clinical trials for its innovative new drug, Nelmastobart, and engaging with multinational pharmaceutical companies to strengthen global competitiveness and diversify its drug pipeline. It is headquartered in Gangnam-gu, Seoul.